14th International Conference on Vectors & Vector Borne Diseases held in Bhubaneswar
Bayer highlights innovations in vector control
- Three-day international conference on vector borne disease management sees support and participation from key public and private organisations
- Bayer’s new water-based insecticide for mosquitoes: Aqua K-Othrine® highlighted as an innovative product to improve public health
Bhubaneswar, January 10, 2019: Rapid urbanization in India has led to a significant rise in Vector Borne Diseases (VBDs) such as Malaria and Dengue. To prevent these diseases, India needs effective and innovative vector control solutions. To highlight the importance of public-private partnership for elimination and control of VBDs, Bayer and the National Academy of Vector Borne Diseases (NAVBD) jointly organised a special session today on “Advancing Health & Well-Being: Vector Control in Action.” The session was part of the 14th International Conference on Vectors & Vector-Borne diseases being held in Bhubaneswar from January 9 to 11.
The common perception is that VBDs are diseases of marginalized communities, since they are endemic in low-income groups or in areas where the vicious cycle of diseases and poverty exists. However, with growth in Aedes borne diseases like Dengue and Chikungunya, nearly everyone is at risk irrespective of their income group. In addition to high mortality, VBDs put an economic burden on society through direct medical costs and indirect costs such as loss of productivity.
Speaking at the conference, Dr. Arun Kumar, Head of Environmental Science at Bayer, South Asia, said: “Bayer strongly believes that challenges to public health require collaboration with multiple stakeholders. In India, Bayer’s Environmental Science unit works closely with Public Health authorities, government organizations and industry associations to implement solutions for preventing VBDs. Bayer is also committed to support the Government of India’s national target for Malaria eradication by 2030 as part of the National Health Mission under the National Vector Borne Disease Control Programme (NVBDCP). We have also been working with NAVBD since 1994.”
Further, Dr. Arun Kumar highlighted Bayer’s new innovation in vector control: Aqua K-Othrine®, which is India’s first water-based space spray insecticide for management of mosquitoes. Speaking about the product, Dr. Arun Kumar, Head of Environmental Science at Bayer, South Asia, said: “At Bayer, we are committed to using science and innovation to improve people’s lives for the better. Our new launch Aqua K-Othrine® will help mitigate the spread of mosquito-borne diseases. We will continue to invest in the research for innovative solutions to improve public health and contribute towards Good Health and Well-Being for People1.”
Aqua K-Othrine® is an emulsion in water (EW) formulation. It contains an anti-evaporant to protect the water-based spray droplets from evaporative water loss. This anti-evaporant technology: FFAST (Film Forming Aqueous Spray Technology) enables Aqua K-Othrine® to be diluted in water without losing efficacy. Being water-based, this innovative product eliminates the use of oil-based diluents such as diesel and helps reduce environmental impact. It also reduces the cost of application by upto 80 percent.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.
Find more information at: https://www.environmentalscience.bayer.in/Vector-Control
Crop Science Communications, Bayer Group in India
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
1Sustainable Development Goal #3: ‘Good Health and Well-Being for People’ as outlined by the United Nations